Life science company Vizgen has introduced its Merscope Protein Co-detection Kit, which enables the simultaneous imaging of proteins and transcripts in a single experiment.
The new kit enables the measurement of subcellular spatial multi-omics by co-detecting RNA and proteins during a standard Multiplexed Error-Robust Fluorescence in situ Hybridization (MERFISH) experiment.
Vizgen noted that RNA imaging helps in resolving gene expression at a single cell level as well as annotating cell states in complex tissues.
However, some information, including morphology and pathological features, can only be imaged by proteins.
The Merscope Protein Stain Reagent Kit enables protein staining that is equal to protein immunofluorescence staining while its oligo conjugated antibodies help to detect primary antibodies targeting proteins.
It can also help in revealing how different RNA transcripts are localised in intracellular organelles.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below formBy GlobalData
Using MERFISH technology, Vizgen’s kit provides next-level transcript staining and enables correlation with bulk RNA-seq data for high, medium and low expressing genes.
Vizgen president and CEO Terry Lo said: “The release of this kit underscores Vizgen’s growing momentum and commitment to our product roadmap, allowing for simultaneous RNA and protein detection in one run while offering the flexibility for users to continue working with their primary antibodies.
“We are excited to provide the scientific community with access to subcellular spatial multi-omics measurements, and to continue developing tools that have the potential to benefit human health.”
The company’s Merscope platform offers insight into a broad range of tissue-scale basic research and translational medicine, including infectious disease, cell and gene therapy, immunology, developmental biology, oncology, and neuroscience.